Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2024 Earnings Presentation
24 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2025
Slide 1: FY2024 Company Update
FY2024 Company Update PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Key Updates
Key Updates
Slide 4: 2024 Key Highlights
2024 Key Highlights Wide network throughout Indonesia with more than 50 years of experience The largest private independent clinical lab chain by size of network and revenue with 40.1%* market share in Indonesia IDR 2.3 Trillion USD 139.4 Million 1973 2012 2016 2022 2024 Founded in 1st and only Inde
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue Innovation to deliver Precision Medicine (in Million) (in IDR Trillion) CAGR CAGR 2.3 >2.7 1.5% 5.2% Offers more than 3,000 type Referral Partnership with >2.5 1.7 o
Slide 6: Business Highlights
Business Highlights
Slide 7: The Largest Independent Lab in Indonesia
The Largest Independent Lab in Indonesia Leading with 40.1% market share of the independent lab market Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2021-2023) (Billion IDR) 5YRS CAGR 5YRS CAGR 37.9% 40.5% 40.1% 6.5% 5.8% 33.1% 28.0% 28.1% 7,225 2,737 2021 2022
Slide 8: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segment Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, General Medical offering the most Genomic Testing Preventive
Slide 9: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Hub and spoke model offers scalable platform reducing Centra
Slide 10: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work Introduced new tests, such as NIPT ProSafe, Amino of more than 500 Marketing and Acid Profile, CArisk, DIArisk, New Born Screen
Slide 11: Strengthen Growth Strategy
Strengthen Growth Strategy To achieve sustainable business through organic expansion, continuous innovation, and comprehensive services Expand our presence and grow our Orchestrate highest quality health network of outlets in both physical and ecosystem and leading digital health digital channel in
Slide 12: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 13: Business Updates
Business Updates
Slide 14: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers 2023 2024 2025 Outlet Development Target 10 4** 11 4** >5 Hospital Labs Management 295 354 149* includes hospital lab & genomic site 148* 133 Outlets Outlets 190 > 70 POC Outlets Point-of
Slide 15: Deliver Solutions for Customer Needs
Deliver Solutions for Customer Needs Highly personalized approach across multiple channels • Routine, Esoteric, Genomic Tests Professional Contact Centre • Prodia for Doctor • Wellness Package • Call Centre 1500-830 • U by Prodia • Disease Screening Package • Chat WhatsApp 0855-1500-830 • ProdiaLink
Slide 16: Financial Updates
Financial Updates
Slide 17: Steady Growth in FY2024 Revenue
Steady Growth in FY2024 Revenue Recorded positive and improving QoQ performance despite market challenges Revenue (Audited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion FY19-FY24 CAGR +5.2% 2018 2019 2020 2021 2022 2023 2024 • 4Q24 revenue shows FY23-FY24 positive improvement Growth:
Slide 18: FY2024 Gross Profit & Net Income
FY2024 Gross Profit & Net Income Shows recovery after soft performance in 2023 Gross Profit Net Income in IDR Billion In IDR Billion FY19-FY24 CAGR +5.4% FY19-FY24 CAGR +5.1% FY23-FY24 FY23-FY24 Gross Profit Margin Net Income Margin Growth: +2.5% Growth: +4.1% 1,633 623.2 61.6% 1,327 1,319 1,352 1,0
Slide 19: FY2024 COGS & OPEX
FY2024 COGS & OPEX COGS decreased along with soft revenue performance, while OPEX remains high COGS OPEX in IDR Billion In IDR Billion FY19-FY24 CAGR +5.1% FY19-FY24 CAGR +4.9% COGS to revenue FY23-FY24 Opex to revenue FY23-FY24 Direct Cost Growth: -0.3% G&A Expense Growth: +3.3% Indirect Cost Marke
Slide 20: FY2024 Financial Summary
FY2024 Financial Summary Financial performance start recovery after soft performance in 2023 (in IDR Bn) FY2024 FY2023 Change (in IDR Bn) FY2024 FY2023 Change Revenue 2,252.2 2,222.5 +1.3% Total Asset 2,840.1 2,708.1 +4.9% Gross Profit 1,352.0 1,319.2 +2.5% Total Equity 2,484.7 2,360.6 +5.3% EBIT 30
Slide 21: Our Professional Team & Shares Information
Our Professional Team & Shares Information
Slide 22: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia 52 Years of 52 Years of 41 Years of 50 Years of 33 Years of Experience Experience Experience Experience Experience Gunawan Endang Joseph Fellipus KeriLestari Keri Lestari Andi
Slide 23: Shareholders Composition
Shareholders Composition Public free float is 28% of total with market cap of IDR 2.53 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 15% 28% Distributor for Contract Research Research, therapy and medical equipment Organization banking of stem cell 39% PT Prodia Widyahusada Tbk Occupati
Slide 24: For further Information
For further Information: PT Prodia Widyahusada Tbk Prodia Tower. Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id @prodia_lab @prodia_lab @prodia_lab 1500 830